Sarah Wakeman

MD, FASAM

Sarah E. Wakeman, MD is the Medical Director for the Mass General Hospital Substance Use Disorder Initiative, program director of the Mass General Addiction Medicine fellowship, and an Assistant Professor of Medicine at Harvard Medical School. She is also the Medical Director of the Mass General Hospital Addiction Consult Team, co-chair of the Mass General Opioid Task Force, and clinical lead of the Partners Healthcare Substance Use Disorder Initiative. She is the Medical Director of RIZE Massachusetts, a state-wide, private sector initiative created to build a $50 million fund to implement and evaluate innovative interventions to address the opioid overdose crisis. She received her A.B. from Brown University and her M.D. from Brown Medical School. She completed residency training in internal medicine and served as Chief Medical Resident at Mass General Hospital. She is a diplomate and fellow of the American Board of Addiction Medicine. She is chair of the policy committee for the Massachusetts Society of Addiction Medicine. She served on Massachusetts' Governor Baker’s Opioid Addiction Working Group. Nationally, she is chair of the American Society of Addiction Medicine Drug Court Task Force and serves on their ethics committee.Clinically she provides specialty addiction and general medical care in the inpatient and outpatient setting at Mass General Hospital and the Mass General Charlestown Health Center. Her research interests include evaluating models for integrated substance use disorder treatment in medical settings, recovery coaching, physician attitudes and practice related to substance use disorder, and screening for substance use in primary care.

Joshua Lee

MD, MSc

Joshua D. Lee MD, MSc is an Associate Professor in the Department of Population Health and the Division of General Internal Medicine and Clinical Innovation at the NYU School of Medicine. He directs the NYU Fellowship in Addiction Medicine. His research focuses on medication treatments for addiction among criminal justice and primary care populations.

Geetha A. Subramaniam

MD, DFAPA, DFAACAP

Geetha is the Deputy Director of the NIDA Center for Clinical Trials Network. She is a accomplished SUD clinician and researacher. In addition to serving as a collaborative scientist on multi-site clinicat trials, she also is focused on forging alliances with medical organizations like ASAM to help inform physicians and allied health professionals by disseminating emerging research information.

Jennifer McNeely

MD, MS

Jennifer McNeely, MD, MS is Associate Professor at the NYU School of Medicine in the Department of Population Health and Department of Medicine, Division of General Internal Medicine. Dr. McNeely is a general internist specialized in Addiction Medicine, and currently practices at Bellevue Hospital. Her research focuses on improving the identification and treatment of substance use disorders in medical settings, and includes developing screening tools and studying their implementation in primary care.

Gavin Bart

MD, PhD, FACP, DFASAM

Dr. Gavin Bart is Director of the Division of Addiction Medicine at Hennepin County Medical Center and Associate Professor of Medicine at the University of Minnesota. He received his MD from the University of Minnesota and trained in internal medicine at the Hennepin County Medical Center. His PhD is in experimental and clinical pharmacology, also from the University of Minnesota. He trained in addiction medicine at The Rockefeller University where he continued as Director of Clinical Research until moving to Minnesota where is is co-PI of the NorthStar Node of the NIDA Clinical Trials Network. His areas of expertise include clinical pharmacology and the pharmacological management of opioid dependence. 

His current research areas include the population pharmacokinetics of methadone, genetic influences of methadone pharmacology and treatment outcome, electronic health record privacy provisions of 42 CFR Part 2, and clinical decision support tool development for SUD. 

He is Chair of the Life-Long Learning and Self-Assessment committee for the American Board of Addiction Medicine and is ASAM Region VI (IA, IL, IN, MI, MN, WI) director. Internationally, he is co-director of the SAMHSA-funded Vietnam HIV and Addiction Technology Transfer Center and provides ongoing technical assistance for the Substance Abuse and Mental Health Administration in South East and Central Asia.

Lisa Marsch

PhD

Lisa A. Marsch, PhD is the Director of the Center for Technology and Behavioral Health (a NIDA-funded P30 Center of Excellence) at Dartmouth College. With funding from NIH, she has led a line of research focused on the development and evaluation of cutting-edge, technology-based (mobile and Internet-delivered) interventions focused on substance abuse treatment among youth and adults, HIV prevention among substance-using youth and adults, substance abuse prevention among children and adolescents, as well as other behavioral health issues. 

These technology-based therapeutic tools reflect an integration of science-based behavioral interventions with evidence-based informational technologies. This work has been conducted in a variety of settings, including physician offices, substance abuse treatment programs, criminal justice settings, primary care settings, educational settings and via the Internet.

Richard F. Camino-Gaztambide

MD, MA

Dr. Richard Camino is an associate professor of Psychiatry and Health Behavior and training director of the general psychiatric residency program at the Medical College of Georgia. Previously, Dr. Camino served as clerkship director and Associate Dean for Diversity and Inclusion at Mercer University. After finishing his Bachelor in Pharmaceutical Sciences from the University of Puerto Rico he graduated from the Universidad Central del Caribe School of Medicine in Puerto Rico. He completed his general psychiatry and child fellowship at the University Of Puerto Rico School Of Medicine. Additionally, Dr. Camino obtained a Masters in Arts in Theology from the University of Notre Dame. He holds board certification in general psychiatry, addiction psychiatry, and child and adolescent psychiatry. He has been active in the American Academy of Child and Adolescent Psychiatry, especially with their Religion and Spirituality Committee, where he is co-chair of the committee. 

Dr. Camino practiced for 17 years in Puerto Rico and was recognized by his peers for 10 consecutive years to the “Doctor Choice Awards” given annually by a Buena Vida Health magazine. As an educator, he has given presentations in Buenos Aires, Medellin, Havana, Caracas, and Santo Domingo. His interests have been in education, cultural psychiatry, religion and spirituality in clinical practice, ADHD in children and adults (where he has done research), and addiction disorders.

Eunice Malave de Leon

MSW, EdD

Eunice Malavé de León is a clinical social worker licensed to practice in several states. She holds a doctorate in education and is co-author in book chapters in several professional publications in family therapy and telemental health. She has extensive experience in cases of child sexual abuse, treating women from domestic violence, reconstituted families and families in underserved populations. Specializes in the management of family dynamics, works with adolescents, adults and the geriatric population. 

Brett Daniel Kaylor

DO

No Bio available

Jonathan Ek

MD

No bio available

David R. Gasfriend

MD, DFASAM

"In his 25 years at Harvard Medical School, Dr. Gastfriend directed the Addiction Research Program at Massachusetts General Hospital and founded the MGH-McLean Addiction Psychiatry Fellowship. His research operationalized and validated ASAM’s Criteria, contributing to their endorsement by most U.S. states, the VA and the Department of Defense. These NIDA- and NIAAA-funded studies led to CONTINUUM - the ASAM Criteria Decision Engine(TM), developed with the support of the U.S. Substance Abuse and Mental Health Services Administration for nationwide release.

From 2004-2013, Dr. Gastfriend was Vice President at Alkermes, Inc., where he supported gaining FDA approval of VIVITROL® for alcohol and opioid dependence and conducted clinical, criminal justice, and health economic research in addiction.
In 2014-2015 he was CEO of the Treatment Research Institute (TRI), the Philadelphia-based international research and policy center. He continues as Scientific Advisor, providing guidance to its researchers on projects such as the Addiction Severity Index and the Kennedy Foundation Parity Monitoring Project.

In 2016, he co-founded, with his son, Eric Gastfriend MBA, DynamiCare Health(TM), to provide a nationally scalable, standardized, low-cost smartphone implementation for contingency management and foster wide-scale adoption of this evidence-based approach to incentivizing healthy recovery behaviors.

NIDA granted him a Mid-Career Investigator Award for Patient-Oriented Research in 2000. In 2007, he received the Boston Business Journal's “Champion in Health Care – Innovator Award”. He is currently Principal Investigator on the $13 million PCORI-funded PATH Study of integrated addiction and primary care. He received ASAM's 2012 McGovern Award and Lecture for contributions to addiction treatment and society. Among his 150 scientific publications are ""The ASAM Criteria"" and ""Addiction Treatment Matching"". He has advised the governments of Belgium, China, Iceland, Israel, Norway, Russia and the U.S. on alcohol and drug addiction treatment. "

David Mee-Lee

MD, FASAM

David Mee-Lee, M.D. is a board-certified psychiatrist, and is certified by the American Board of Addiction Medicine (ABAM). Based in Davis, California, he trains and consults both nationally and internationally.  Dr. Mee-Lee is Chief Editor of the American Society of Addiction Medicine's (ASAM) Criteria for the Treatment of Addictive, Substance-Related, and Co-Occurring Conditions and is President of DML Training and Consulting. He is co-founder of the Institute for Wellness Education. Dr. Mee-Lee has forty years of experience in person centered treatment and program development for people with co-occurring mental health and substance use conditions.

Paul H. Earley

MD, DFASAM

Dr. Earley has worked in Addiction Medicine for over 30 years. He treats all types of addictive disorders and specializes in the assessment, treatment and management of health care professionals. As a therapist, he works with patients already in recovery, providing long term therapy for those who suffer from this disease. His professional expertise extends to advocacy for professionals before agencies and licensing boards. 

Dr. Earley is a dynamic speaker and educator; he speaks and trains on topics of addiction, its treatment and addiction among health care professionals. In addition, he trains therapists about the neurobiological basis of psychotherapy. In his travels, he has provided training in the United States, Canada, the United Kingdom, Italy, Iceland and Switzerland.

He is the author of two books and several research articles on addiction and its treatment. His most recent book, RecoveryMind Training is an innovative and comprehensive process designed to reengineer addiction treatment. He is a contributing author to the American Society of Addiction Medicine (ASAM) Textbook: Principles of Addiction Medicine, as author of the chapter: Physician Health Programs and Addiction among Physicians. He is a contributing author to the ASAM Criteria. His work was featured in the documentary series on addiction entitled Close to Home by Bill Moyers.

Currently, Dr. Earley is the Medical Director of the Georgia Professionals Health Program, Inc., the Physicians Health Program (PHP) for the state of Georgia and the President-elect of the Federation of State Physician Health Programs (FSPHP). Dr. Earley is the current president-elect of the American Society of Addiction Medicine (ASAM). He is a Distinguished Fellow of ASAM and has served on the board of ASAM for over 14 years in several capacities.

Gary Tsai

MD, FASAM, FAPA

Gary Tsai, M.D. is board certified in both general adult psychiatry and addiction medicine, and is the Medical Director and Science Officer of the Substance Abuse Prevention and Control, a division of the Los Angeles County Department of Public Health. In this role, he is responsible for providing clinical leadership to oversee substance use disorder (SUD) research, epidemiology and evaluation, as well as a full spectrum of SUD prevention, treatment, and recovery support services for the 10 million residents of Los Angeles County. He continues clinical practice at Cedars-Sinai Medical Center, and is a member of the Advisory Board of the Treatment Advocacy Center and Partners for StrongMinds, a former APA / SAMHSA Minority Fellow, and is active in the LPS Reform Task Force. 

Having experienced the stigma and criminalization that often accompanies serious mental illness as the son of a mother with schizophrenia, Dr. Tsai is a passionate advocate for improving our behavioral health systems. In his pursuit of meaningful change, Dr. Tsai is also the founder of Forgotten Films, a film production company focusing on social issue projects, specializing in behavioral health. Its first film, "Voices," premiered on public television in May 2015 for Mental Health Awareness Month and was awarded a 2016 SAMHSA Voice Award, Honorable Mention.

George F. Koob

PhD

George F. Koob, PhD is Director of the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health, Washington, DC. As an authority on alcoholism, drug addiction and stress, he has contributed to our understanding of the neurocircuitry associated with the acute reinforcing effects of alcohol and drugs of abuse and the neuroadaptations of the reward and stress circuits associated with the transition to dependence. Dr. Koob has published over 650 peer reviewed papers and several books including the “Neurobiology of Addiction," a comprehensive treatise on emerging research in the field. He has mentored 11 PhD students and over 75 post-doctoral fellows.

Wilson Compton

MD, MPE

Dr. Wilson M. Compton serves as the Deputy Director of the National Institute on Drug Abuse (NIDA) of the National Institutes of Health. In his current role, Dr. Compton's responsibilities include providing scientific leadership in the development, implementation, and management of NIDA's research portfolio and working with the Director to support and conduct research to improve the prevention and treatment of drug abuse and addiction. Prior to his current appointment, Dr. Compton served as the Director of NIDA's Division of Epidemiology, Services and Prevention Research from 2002 until 2013. In this leadership role, he oversaw the scientific direction of a complex public health research program of national and international scope addressing: 1) the extent and spread of drug abuse, 2) how to prevention drug abuse, and 3) how to implement drug abuse prevention and treatment services as effectively as possible. Before joining NIDA, Dr. Compton was Associate Professor of Psychiatry and Director of the Master in Psychiatric Epidemiology Program at Washington University in Saint Louis as well as Medical Director of Addiction Services at the Barnes-Jewish Hospital in Saint Louis. Dr. Compton received his undergraduate education from Amherst College. He attended medical school and completed his residency training in psychiatry at Washington University. During his career, Dr. Compton has achieved multiple scientific accomplishments: he was selected to serve as a member of the DSM-5 Revision Task Force; is the author of more than 130 articles and chapters; and is an invited speaker at multiple high-impact venues. Dr. Compton is the recipient of multiple awards and in 2008, he received the Senior Scholar Health Services Research Award from the American Psychiatric Association, in 2010 the Paul Hoch Award from the American Psychopathological Association, in both 2012 and 2013, he was selected to receive the Leveraging Collaboration Award from the Food and Drug Administration. In 2013, Dr. Compton received the prestigious Health and Human Services Secretary's Award for Meritorious Service.

Debbie Dowell

MD, MPH

Debbie Dowell is Senior Medical Advisor/Chief Medical Officer for the Division of Unintentional Injury Prevention at the Centers for Disease Control and Prevention (CDC), CDR in the US Public Health Service, and was the lead author of the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain. She previously led CDC’s Prescription Drug Overdose Team and served as advisor to New York City’s Health Commissioner. Dr. Dowell completed residency and chief residency in Primary Care Internal Medicine at the NYU School of Medicine, where she later joined the faculty as a clinical assistant professor. Dr. Dowell is Board Certified in Internal Medicine and practiced medicine at a community health center in New York City.

She has conducted research on quality and safety in medical care, on the effects of clinical guidelines, and on the effectiveness of interventions to prevent opioid overdose, including Prescription Drug Monitoring Programs and academic detailing. She received her BA and MD from Columbia University, her MPH from the Johns Hopkins Bloomberg School of Public Health, and is a graduate of CDC’s Epidemic Intelligence Service (EIS).

Kelly Clark (Moderator)

MD, MBA, DFASAM, DFAPA

Dr. Kelly J. Clark is the President Elect of ASAM. She currently chairs the Public Policy Council, consisting of the Legislative Advocacy, Payer Relations, and Public Policy Committees.

Board certified in addiction medicine and psychiatry, she has focused her career on issues of prescription drug abuse, evidence informed behavioral health care, and payment reform. Dr. Clark is Chief Medical Officer of CleanSlate Centers, a multi-state medical group currently treating over 5,000 opioid addicted patients with medication management, and which has received a SAMHSA Science to Service Award for Office Based Opioid Treatment. She is active on the Association of Managed Care Pharmacy's Addiction Treatment Advisory Group; served on the writing committee of the Johns Hopkins Bloomberg School of Public Health's recent policy document, “The Prescription Drug Epidemic: An Evidence Based Approach”; and led the workgroup on Health Systems and Reimbursement at SAMHSA's Buprenorphine Summit.

As the Behavioral Health Medical Director of CDPHP, a non-profit health plan in New York, she provided the clinical leadership for in-sourcing the management of behavioral health benefits. As Chief Medical Officer for Behavioral Health Group, she again focused on opioid addiction. Her expertise in payment models, quality metrics, medical-behavioral health integration, and clinical care delivery systems, as well as her clinical work treating people with addictive disease, all allow her to offer insights and recommendations to address the current epidemic.

As faculty of the University of Massachusetts Medical School for eight years, Dr. Clark trained students and resident physicians on addiction. She is currently a member of the American Psychiatric Association's Integrated Care Work Group; the National Rx Drug Abuse Summit Advisory Board; and the faculty of the Virginia Tech Carilion School of Medicine.

Marcia Jackson

PhD

Dr. Marcia Jackson is President of CME by Design, a consulting group that provides the full range of instructional design services in the field of continuing medical education. Dr. Jackson served as division vice president and senior advisor for education at the American College of Cardiology from 1992-2007. She is a past President of the Alliance for Continuing Medical Education, a past member of the National Task Force on CME Provider/Industry Collaboration, and current chair of the Medscape Education Advisory Board, She is a recipient of the ACCME Robert Razskowski Award and the Alliance for CME Distinguished Service Award.  She has been an ASAM consultant since 2013.

Mike Monahan

MEd, RN

Mike Monahan MEd, RN  President, Healthcare Resources Associates.  Mike provides performance improvement coaching, consulting and training serving the learning and development needs of individuals, teams, and organizations primarily in healthcare.  He has developed a particular interest in the needs of leaders facing the personal and professional challenges of today’s workplace.  He has been focusing on helping teams and individuals improve measurable performance and tend to the human side of work relationships.  Mike serves as a faculty development consultant for the American College of Cardiology and Mayo.  Mike is a frequent speaker at professional conferences and has published in journals as well as co-authoring several books.

Lon R. Hays

MD, MBA, DFAPA, DFASAM

Lon Roberts Hays, M.D., M.B.A. graduated from medical school at the University of Kentucky in 1982 then pursued residency training at the University of Kentucky, which he completed in 1986. At that time he joined the faculty in the Department of Psychiatry where he has served as Chair from 1998 to 2018, and is director of the Addiction Medicine Fellowship.  In addition to being Board Certified by the American Board of Psychiatry and Neurology, Dr. Hays also is certified by the American Board of Addiction Medicine and has Added Qualifications in both Addiction Psychiatry and Geriatric Psychiatry. He completed a Certificate of Medical Management in 1998 and went on to obtain his M.B.A. from the University of Kentucky Gatton School of Business in May 2001.  Dr. Hays is a Co-investigator on numerous grants involving drugs of abuse.  He is the Director of Area V of the American Academy of Addiction Psychiatry, President of the Addiction MedicineFoundation, a Distinguished Fellow of the American Psychiatric Association, and an elected member and Fellow of the American College of Psychiatrists."

Randall Brown

MD, PhD, DFASAM

Dr. Brown is on the Board of Directors of The Addiction Medicine Foundation and is President-Elect of the Addiction Medicine Fellowship Directors Association. He is Board Certified in Family Medicine and Addiction Medicine. He has been heavily involved in fellowship development at the program for which he was the founding Director at the University of Wisconsin School of Medicine and Public Health, as well as at the national level. He serves as a consulting physician in addiction medicine at UW Hospital (where he is the Director of the Center for Addictive Disorders), William S. Middleton Memorial Veterans Hospital, the UW Hospital HIV/AIDS Clinic, and at Access Community Health Centers (a network of Federally Qualified Health Centers). Dr. Brown is also the Director of the UW SMPH fourth year Clinical Addiction Elective, and the Medical Director of the Overdose Prevention Program of the AIDS Resource Center of Wisconsin. Dr. Brown holds a PhD in Population Health Sciences from the University of Wisconsin.

Timothy K. Brennan

MD, MPH, FASAM

Timothy Brennan, MD, MPH, FASAM is an Addiction Medicine physician and Pediatrician. He is the Director of the Addiction Institute at Mount Sinai West and St. Luke's Hospitals in New York City and the Vice President for Medical and Academic Affairs at The Addiction Medicine Foundation. He is also the Director of the Fellowship in Addiction Medicine at the Icahn School of Medicine at Mount Sinai. He completed a Fellowship in Addiction Medicine at the Addiction Institute of New York, a Fellowship in Medical Ethics at Harvard Medical School, a Residency in Pediatrics at Weill Cornell Medical College / New York Presbyterian Hospital, and an Internship in Internal Medicine at Georgetown University Hospital. He is the Co-Editor of Essentials of Addiction Medicine and Board Certified in Addiction Medicine and Pediatrics.

Jeanette M. Tetrault

MD, FACP, FASAM

Dr. Tetrault’s scholarly work focuses on care of patients with addicition and the medical co-morbidities associated with substance use, mainly HIV and Hepatitis C. She is a diplomate of the American Board of Addiction Medicine. Dr. Tetrault is a physician providing primary care and buprenorphine/naloxone treatment at the Central Medical Unit of the APT Foundation, a multi-specialty addiction treatment facility, and is an attending physician at Yale New Haven Hospital (YNHH). She is the co-director of the Addiction Recovery Clinic in the Adult Primary Care Clinic at the St. Raphael's Campus of YNHH, which serves both a clinical care and a teaching mission. She was selected as a Macy Foundation Faculty Scholar in 2017. She is the Program Director for the Yale Addiction Medicine Fellowship Program and serves on the Board of Directors for The Addiction Medicine Foundation and the Addiction Medicine Fellowship Directors Association. She is a past-president of the New England Region of SGIM and co-chair of the Alcohol, Tobacco and Other Drug Use Interest Group for SGIM.

Christopher J. Ondrula

JD

Christopher J. Ondrula, is the Executive Director of the American Board of Preventative Medicine (ABMS).  Prior to joining ABMS in 2015, Mr. Ondrula served as the Chief Executive Officer and Director at Heartland Food Corporation, and the former Chief Operating Officer and General Counsel for Spence Group Services.

A graduate of Miami University in Oxford, Ohio, Mr. Ondrula received his Juris Doctorate from Valparaiso University School of Law. Initially practicing in Chicago area law firms where his practice
focused on the defense of medical malpractice claims and product liability litigation, he later joined the Arena Football League as its Assistant General Counsel.

Michael F. Weaver

MD, DFASAM

Dr. Michael Weaver is Professor of Psychiatry and Medical Director of the Center for Neurobehavioral Research on Addiction at The University of Texas McGovern Medical School at Houston. He completed a Residency in Internal Medicine and a Clinical Research Fellowship in Addiction Medicine at Virginia Commonwealth University. He is involved in patient care, medical education, and research. Dr. Weaver has multiple publications in the field of addiction medicine. He treats patients at the Innovations Addiction Treatment Clinic at the Texas Medical Center in Houston, which provides medication-assisted treatment. He is the Sub-Board Chair for Addiction Medicine for the American Board of Preventive Medicine.  He is a member of the ASAM Publications Council and on the Editorial Board for the Journal of Addiction Medicine.

Michael M. Miller

MD, LFAPA, DFASAM

Michael M. Miller, MD, DFASAM, LFAPA, is the medical director of the Herrington Recovery Center at Rogers Memorial Hospital in Oconomowoc, Wisconsin. He is a board-certified general psychiatrist and addiction psychiatrist. Dr. Miller has practiced addiction medicine for more than 30 years and is certified in addiction medicine by the American Board of Addiction Medicine. He is a Life Fellow of the American Psychiatric Association (APA) and a Distinguished Fellow of the American Society of Addiction Medicine (ASAM). Dr. Miller is also an at-large director of the American Board of Addiction Medicine (ABAM) and The ABAM Foundation, as well as a past president of ASAM. Dr. Miller has served on many task forces and councils of ASAM and the Wisconsin Medical Society (WMS), was chair of the WMS Commission on Addictive Diseases, and is current Speaker of the WMS House of Delegates and a member of the Society's Board of Directors. He serves as a faculty member for the Addiction Psychiatry Fellowship and the Addiction Medicine Fellowship at the University of Wisconsin School of Medicine and Public Health, where he is a Clinical Adjunct Professor. He also is an assistant clinical professor in the Department of Psychiatry and Behavioral Medicine at the Medical College of Wisconsin. Dr. Miller was named the national physician Clinician of the Year by Addiction Professional magazine in 2011. He was the recipient of The ASAM Award in 2013.. Through 2015, he chaired the Steering Committee of ASAM's Practice Improvement and Performance Measurement Action Group. In June 2014, Dr. Miller was elected by the AMA House of Delegates to a four year term on the AMA Council on Science and Public Health.